ATOS vs. VACC, OGI, ME, LFCR, ALIM, OMER, CAPR, RIGL, GLSI, and SKYE
Should you be buying Atossa Therapeutics stock or one of its competitors? The main competitors of Atossa Therapeutics include Vaccitech (VACC), Organigram (OGI), 23andMe (ME), Lifecore Biomedical (LFCR), Alimera Sciences (ALIM), Omeros (OMER), Capricor Therapeutics (CAPR), Rigel Pharmaceuticals (RIGL), Greenwich LifeSciences (GLSI), and Skye Bioscience (SKYE). These companies are all part of the "pharmaceutical preparations" industry.
Atossa Therapeutics (NASDAQ:ATOS) and Vaccitech (NASDAQ:VACC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings, community ranking and institutional ownership.
Atossa Therapeutics has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, Vaccitech has a beta of -0.4, meaning that its share price is 140% less volatile than the S&P 500.
Atossa Therapeutics received 211 more outperform votes than Vaccitech when rated by MarketBeat users. However, 70.83% of users gave Vaccitech an outperform vote while only 64.96% of users gave Atossa Therapeutics an outperform vote.
In the previous week, Atossa Therapeutics had 2 more articles in the media than Vaccitech. MarketBeat recorded 4 mentions for Atossa Therapeutics and 2 mentions for Vaccitech. Vaccitech's average media sentiment score of 0.41 beat Atossa Therapeutics' score of 0.04 indicating that Vaccitech is being referred to more favorably in the news media.
Atossa Therapeutics presently has a consensus target price of $4.50, indicating a potential upside of 216.90%. Vaccitech has a consensus target price of $7.63, indicating a potential upside of 191.03%. Given Atossa Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Atossa Therapeutics is more favorable than Vaccitech.
12.7% of Atossa Therapeutics shares are held by institutional investors. Comparatively, 26.1% of Vaccitech shares are held by institutional investors. 7.8% of Atossa Therapeutics shares are held by insiders. Comparatively, 6.0% of Vaccitech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Atossa Therapeutics has a net margin of 0.00% compared to Vaccitech's net margin of -409.18%. Vaccitech's return on equity of -23.41% beat Atossa Therapeutics' return on equity.
Vaccitech has higher revenue and earnings than Atossa Therapeutics. Atossa Therapeutics is trading at a lower price-to-earnings ratio than Vaccitech, indicating that it is currently the more affordable of the two stocks.
Summary
Atossa Therapeutics beats Vaccitech on 9 of the 17 factors compared between the two stocks.
Get Atossa Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Atossa Therapeutics Competitors List
Related Companies and Tools
